On April 30, Cinda Biopharmaceuticals announced the appointment of Samuel Zhang (Samuel Zhang) as the Global Chief Commercial Officer (CBO). Zhang Suhua will report to Yu Dechao, the founder, chairman and CEO of the company, who is responsible for the strategic planning and business development of Cinda Biotech's global business. Prior to joining Cinda Biotech, Zhang Suhua was the chief commercial officer of Genxi Biotech and NeoImmune Tech, leading the $1.2 billion acquisition partnership between Genxi Biotech and AstraZeneca. He has also held various management positions at Eli Lilly, Pfizer, Bristol-Myers Squibb, Novartis, and Merus.
4月30日信达生物制药宣布任命张苏华（Samuel Zhang）为全球首席商务官（CBO）。张苏华将负责信达生物在全球业务的战略规划和商务拓展工作向公司创始人、董事长兼首席执行官俞德超汇报。张苏华在加入信达生物之前曾担任亘喜生物和NeoImmune Tech公司首席商务官主导了亘喜生物与阿斯利康价值12亿美元的收购合作。他还曾在礼来、辉瑞、百时美施贵宝、诺华以及Merus公司担任过各类管理岗位。
On April 30, Cinda Biopharmaceuticals announced the appointment of Samuel Zhang (Samuel Zhang) as the Global Chief Commercial Officer (CBO). Zhang Suhua will report to Yu Dechao, the founder, chairman and CEO of the company, who is responsible for the str
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.